BioCentury
ARTICLE | Company News

Receptos, AbbVie partner for AbbVie's IL-13 mAb

March 14, 2013 12:30 AM UTC

Receptos Inc. (San Diego, Calif.) licensed from AbbVie Inc. (NYSE:ABBV) RPC4046, a humanized mAb against IL-13 that has completed Phase I testing. Receptos will conduct a Phase II trial of RPC4046 to ...